Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
+0.17 (4.11%)
Apr 16 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 4.18 - 4.31
52 week 1.90 - 4.74
Open 4.18
Vol / Avg. 229,413.00/355,076.00
Mkt cap 183.52M
P/E     -
Div/yield     -
EPS -0.44
Shares 42.58M
Beta 1.89
Inst. own 33%
Jun 9, 2014
Q3 2014 Enzo Biochem Earnings Release (Estimated) Add to calendar
Apr 8, 2014
Enzo Biochem at Needham Healthcare Conference
Mar 12, 2014
Q2 2014 Enzo Biochem Earnings Conference Call - Webcast
Mar 11, 2014
Q2 2014 Enzo Biochem Earnings Release
Jan 17, 2014
Enzo Biochem Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '13) 2013
Net profit margin -11.55% -19.46%
Operating margin -12.51% -20.25%
EBITD margin - -15.34%
Return on average assets -19.07% -28.48%
Return on average equity -33.26% -43.82%
Employees 423 -
CDP Score - -


United States - Map
+1-516-7555500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Enzo Biochem, Inc. (Enzo), is an integrated life sciences and biotechnology company. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. Enzo focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. The Company has developed a portfolio of technologies with a variety of research, diagnostic and therapeutic applications. Enzo Clinical Labs segment is a regional clinical laboratory serving the New York, New Jersey and Eastern Pennsylvania medical communities. The Company's Enzo Life Sciences manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers world-wide. The Company's Enzo Therapeutics segment is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 69
Bio & Compensation  - Reuters
Andrew R. Crescenzo CPA Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Herbert B. Bass Vice President - Finance
Age: 64
Bio & Compensation  - Reuters
Paul C O'Brien Vice President - Global Human Resources
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development; Interim General Manager of Enzo Clinical Labs
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew P. Whiteley Chief Operating Officer of Enzo Life Sciences, Inc.,
Age: 54
Bio & Compensation  - Reuters
Bernard L. Kasten Jr., M.D. Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Dov Perlysky Director
Age: 50
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 43
Bio & Compensation  - Reuters